scPharmaceuticals reports Q4 EPS (30c), consensus (39c)

scPharmaceuticals ended the fourth quarter 2022 with $118.4M in cash, cash equivalents, restricted cash and investments, compared to $75.5 million as of December 31, 2021."While it has only been a few weeks since the launch and commercial availability of FUROSCIX, interest among patients, providers, and payers is strong, reflecting the important role that FUROSCIX can play in the heart failure treatment paradigm, either pre-hospital admission or post-discharge," said John Tucker, President and Chief Executive Officer of scPharmaceuticals. "We believe FUROSCIX is a true game changer, as it allows patients to access IV-equivalent furosemide, based on similar systemic exposure and diuresis, in the comfort of their own homes. We believe we have a strong balance sheet and a world class commercial team, and I am confident that we will quickly get FUROSCIX to the many heart failure patients who stand to benefit from it." "In parallel, our discussions with payers are ongoing, and we continue to work tirelessly to achieve the broadest, most affordable patient access to this important new heart failure treatment alternative," Mr. Tucker concluded.